AU2022368930A1 - Factor xi a2 domain-binding antibodies and methods of use thereof - Google Patents

Factor xi a2 domain-binding antibodies and methods of use thereof Download PDF

Info

Publication number
AU2022368930A1
AU2022368930A1 AU2022368930A AU2022368930A AU2022368930A1 AU 2022368930 A1 AU2022368930 A1 AU 2022368930A1 AU 2022368930 A AU2022368930 A AU 2022368930A AU 2022368930 A AU2022368930 A AU 2022368930A AU 2022368930 A1 AU2022368930 A1 AU 2022368930A1
Authority
AU
Australia
Prior art keywords
fxi
antibody
antigen
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022368930A
Other languages
English (en)
Inventor
Dan CHALOTHORN
Kehdih LAI
Lori MORTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2022368930A1 publication Critical patent/AU2022368930A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022368930A 2021-10-22 2022-10-21 Factor xi a2 domain-binding antibodies and methods of use thereof Pending AU2022368930A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163270629P 2021-10-22 2021-10-22
US63/270,629 2021-10-22
PCT/US2022/078530 WO2023070097A2 (en) 2021-10-22 2022-10-21 Factor xi a2 domain-binding antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2022368930A1 true AU2022368930A1 (en) 2024-05-02

Family

ID=84360943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022368930A Pending AU2022368930A1 (en) 2021-10-22 2022-10-21 Factor xi a2 domain-binding antibodies and methods of use thereof

Country Status (12)

Country Link
US (1) US12304969B2 (https=)
EP (1) EP4419142A2 (https=)
JP (1) JP2024539157A (https=)
KR (1) KR20240099304A (https=)
CN (1) CN118414168A (https=)
AU (1) AU2022368930A1 (https=)
CA (1) CA3235457A1 (https=)
CL (1) CL2024001237A1 (https=)
CO (1) CO2024006258A2 (https=)
IL (1) IL312308A (https=)
MX (1) MX2024004849A (https=)
WO (1) WO2023070097A2 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US8388959B2 (en) 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
TWI736575B (zh) * 2016-01-22 2021-08-21 美商默沙東藥廠 抗凝固因子ｘｉ抗體
CA3125303A1 (en) 2019-01-21 2020-07-30 Aronora Inc. Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof

Also Published As

Publication number Publication date
EP4419142A2 (en) 2024-08-28
CN118414168A (zh) 2024-07-30
KR20240099304A (ko) 2024-06-28
CL2024001237A1 (es) 2024-09-13
WO2023070097A2 (en) 2023-04-27
US12304969B2 (en) 2025-05-20
US20230131338A1 (en) 2023-04-27
IL312308A (en) 2024-06-01
MX2024004849A (es) 2024-05-06
CA3235457A1 (en) 2023-04-27
WO2023070097A3 (en) 2023-06-08
CO2024006258A2 (es) 2024-06-27
JP2024539157A (ja) 2024-10-28

Similar Documents

Publication Publication Date Title
JP7759417B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
US20230235068A1 (en) Antigen-binding proteins that antagonize leptin receptor
AU2011258342A1 (en) Antibodies to human GDF8
JP2024116399A (ja) 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
CA3109513A1 (en) Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
US12304969B2 (en) Factor XI A2 domain-binding antibodies and methods of use thereof
US20240190996A1 (en) Factor xi catalytic domain-binding antibodies and methods of use thereof
EA052707B1 (ru) Антитела, связывающие домен a2 фактора xi, и способы их использования
CN121568964A (zh) 抗因子XII/XIIa抗体及其用途
EA048528B1 (ru) АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ